Analysts Set INmune Bio, Inc. (NASDAQ:INMB) Price Target at $22.80

Shares of INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are currently covering the firm, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $22.80.

A number of analysts recently weighed in on INMB shares. RODMAN&RENSHAW upgraded shares of INmune Bio to a "strong-buy" rating in a research note on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a "buy" rating and a $23.00 target price for the company. Scotiabank boosted their price target on INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a research report on Tuesday, February 11th. Finally, Maxim Group increased their price objective on INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th.

Institutional Investors Weigh In On INmune Bio

A number of hedge funds have recently added to or reduced their stakes in the company. Barclays PLC increased its position in INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company's stock worth $157,000 after purchasing an additional 24,906 shares during the period. Rhumbline Advisers grew its holdings in INmune Bio by 16.9% during the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company's stock worth $78,000 after acquiring an additional 2,424 shares during the period. Raymond James Financial Inc. purchased a new position in INmune Bio in the fourth quarter worth $2,221,000. Jane Street Group LLC acquired a new stake in INmune Bio in the third quarter valued at $79,000. Finally, Geode Capital Management LLC boosted its position in shares of INmune Bio by 6.6% during the 3rd quarter. Geode Capital Management LLC now owns 344,466 shares of the company's stock worth $1,857,000 after purchasing an additional 21,262 shares in the last quarter. Institutional investors and hedge funds own 12.72% of the company's stock.

INmune Bio Stock Up 2.2 %

INMB traded up $0.17 on Tuesday, reaching $7.76. The company had a trading volume of 224,791 shares, compared to its average volume of 252,712. INmune Bio has a 1 year low of $4.32 and a 1 year high of $11.76. The stock has a market capitalization of $178.36 million, a PE ratio of -3.56 and a beta of 1.86. The stock has a 50-day moving average price of $7.76 and a 200-day moving average price of $6.81.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.14. As a group, analysts expect that INmune Bio will post -2.24 earnings per share for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.